Regulatory Advocacy

The AAO-HNS has a long history of working closely with regulatory agencies (e.g., Centers for Medicare & Medicaid Services, U.S. Food and Drug Administration) to maintain our visibility and credibility with national representatives regarding federal regulatory issues.

We believe that advocacy is the key to defining the future of otolaryngology. Federal regulatory advocacy is a top priority of the AAO-HNS.

Academy Signs onto Letter Requestings a Pause for Meaningful Use Stage 3 Implementation
On September 17, the Academy signed onto a letter requesting the Department of Health and Human Services and the Office of Management and Budget to pause the implementation of Meaningful Use (MU) Stage 3. The letter asked for a pause due to the delay in publishing the Modifications Rule and the ambiguity surrounding the implementation of Merit-Based Payment System (MIPS) and Alternative Payment Models (APMs). Read the letter

Academy Comments on Proposed 2016 Physician Fee Schedule
On September 8, the Academy submitted comments to CMS regarding the 2016 Proposed Medicare Physician Fee Schedule (MPFS). Topics addressed include: proposed practice expense changes; Global Surgical Package valuation; Physician Quality Reporting System and Qualified Clinical Data Registry (QCDR) requirements; Merit-based Incentive Payment System (MIPPS) establishment; and Alternative Payment Model (APM) regulations. Read the letter.

Looking for the AAO-HNS summary of the CY 2016 Proposed Medicare Physician Fee Schedule? Read the summary.

Academy Comments on Proposed CY 2016 HOPPS (8/31/15)
The Academy submitted comments on the proposed rule for CY 2016 Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) Payment Rate that are specifc to the Otolaryngology community. The Academy commented on: point-of-care imaging access for patients and changes to Ambulatory Payment Classifications assignments. Read the letter.